Skip to main content

Advertisement

Table 3 Subgroup analysis of long-term survivors in complete remission with (CTx, n = 4) and without completion of full recommended chemotherapy regimen (no CTx, n = 4)

From: Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data

 CTxnoCTx
 Median (range)Median (range)
Age (years)69 (65–70)57 (30–84)
BMI (kg/m2)23.4 (23–32)24.5 (23–25)
 n (%)
Gender (female/male)4/0 (100/0%)3/1 (75/25%)
Smokers0 (0%)1 (25%)
Alcohol abuse0 (0%)0 (0%)
ASA Score [12]
 I1 (25%)0 (0%)
 II2 (50%)2 (50%)
 III1 (25%)2 (50%)
 IV0 (0%)0 (0%)
Common comorbidities
 Hypertension1 (25%)3 (75%)
 Post pancreatitis2 (50%)2 (50%)
 Hepatic disease1 (25%)0 (0%)
 Coronary heart disease0 (0%)0 (0%)
 Pulmonary disease0 (0%)0 (0%)
 Renal insufficiency0 (0%)1 (25%)
 Diabetes1 (25%)0 (0%)
Localization of tumor
 Head3 (75%)4 (100%)
 Body1 (25%)0 (0%)
 Tail0 (0%)0 (0%)
Grading of tumor
 G23 (75%)4 (100%)
 G30 (0%)0 (0%)
 G41 (25%)0 (0%)
Invasion of lymph nodes (N)
 N02 (50%)2 (50%)
 N12 (50%)2 (50%)
Type of surgery
 Pancreatoduodenectomy3 (75%)4 (100%)
 Distal pancreatectomy1 (25%)0 (0%)
 Total pancreatectomy0 (0%)0 (0%)
Complications
 Intraoperative complication0 (0%)0 (0%)
 Postoperative complication3 (75%)2 (50%)
 Operative revision0 (0%)0 (0%)
 Median (range)Median (range)
Hospital stay (days)
 Overall17 (14–45)21 (16–31)
 Intensive care unit5 (3–6)7 (4–7)
Drain remove (days)6 (3–45)7 (5–8)